127 related articles for article (PubMed ID: 38619000)
21. Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population.
Alomari M; Covut F; Al Momani L; Chadalavada P; Hitawala A; Young MF; Romero-Marrero C
JGH Open; 2020 Apr; 4(2):132-139. PubMed ID: 32280755
[TBL] [Abstract][Full Text] [Related]
22. [The effect of Cathepsin S in primary biliary cholangitis].
Luo X; Li X; Du ZR; Peng Y; Deng CW; Fei YY
Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(7):505-509. PubMed ID: 30786347
[No Abstract] [Full Text] [Related]
23. Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study.
Ho PJ; Tan IB; Chong DQ; Khor CC; Yuan JM; Koh WP; Dorajoo R; Li J
Elife; 2023 Mar; 12():. PubMed ID: 36971353
[TBL] [Abstract][Full Text] [Related]
24. Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis.
Dyson JK; Blain A; Foster Shirley MD; Hudson M; Rushton S; Jeffreys Jones DE
JHEP Rep; 2021 Feb; 3(1):100202. PubMed ID: 33474546
[TBL] [Abstract][Full Text] [Related]
25. New insights on the role of human leukocyte antigen complex in primary biliary cholangitis.
Mulinacci G; Palermo A; Gerussi A; Asselta R; Gershwin ME; Invernizzi P
Front Immunol; 2022; 13():975115. PubMed ID: 36119102
[TBL] [Abstract][Full Text] [Related]
26. A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score.
Patanwala I; McMeekin P; Walters R; Mells G; Alexander G; Newton J; Shah H; Coltescu C; Hirschfield GM; Hudson M; Jones D
J Hepatol; 2013 Aug; 59(2):327-35. PubMed ID: 23608623
[TBL] [Abstract][Full Text] [Related]
27. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.
Carbone M; Sharp SJ; Flack S; Paximadas D; Spiess K; Adgey C; Griffiths L; Lim R; Trembling P; Williamson K; Wareham NJ; Aldersley M; Bathgate A; Burroughs AK; Heneghan MA; Neuberger JM; Thorburn D; Hirschfield GM; Cordell HJ; Alexander GJ; Jones DE; Sandford RN; Mells GF;
Hepatology; 2016 Mar; 63(3):930-50. PubMed ID: 26223498
[TBL] [Abstract][Full Text] [Related]
28. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
29. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive prediction of insufficient biochemical response after ursodeoxycholic acid treatment in patients with primary biliary cholangitis based on pretreatment nonenhanced MRI.
Zhang Y; Fan X; Song B; Liu Y; Chen Y; Zheng T; Guo Y; Duan T; Huang Z; Yang L
Eur Radiol; 2024 Feb; 34(2):1268-1279. PubMed ID: 37581659
[TBL] [Abstract][Full Text] [Related]
31. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
[TBL] [Abstract][Full Text] [Related]
32. NFKB1 and MANBA Confer Disease Susceptibility to Primary Biliary Cholangitis via Independent Putative Primary Functional Variants.
Hitomi Y; Nakatani K; Kojima K; Nishida N; Kawai Y; Kawashima M; Aiba Y; Nagasaki M; Nakamura M; Tokunaga K
Cell Mol Gastroenterol Hepatol; 2019; 7(3):515-532. PubMed ID: 30528300
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease.
Vesterhus M; Nielsen MJ; Hov JR; Saffioti F; Manon-Jensen T; Leeming DJ; Moum B; Boberg KM; Pinzani M; Karlsen TH; Karsdal MA; Thorburn D
JHEP Rep; 2021 Feb; 3(1):100178. PubMed ID: 33225252
[TBL] [Abstract][Full Text] [Related]
34. Novel
Khor SS; Ueno K; Nishida N; Kawashima M; Kawai Y; Aiba Y; Hitomi Y; Nagasaki M; Nakamura M; Tokunaga K
Front Immunol; 2023; 14():1151502. PubMed ID: 37325616
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.
Bosch DE; Zen Y; Boukhar SA; Liu Y; Cheng L; Yeh MM
Virchows Arch; 2021 Dec; 479(6):1131-1143. PubMed ID: 34414507
[TBL] [Abstract][Full Text] [Related]
36. Combining polygenic risk scores and human leukocyte antigen variants for personalized risk assessment of type 1 diabetes in the Taiwanese population.
Liao WL; Huang YN; Chang YW; Liu TY; Lu HF; Tiao ZY; Su PH; Wang CH; Tsai FJ
Diabetes Obes Metab; 2023 Oct; 25(10):2928-2936. PubMed ID: 37455666
[TBL] [Abstract][Full Text] [Related]
37. S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.
Dong XH; Dai D; Yang ZD; Yu XO; Li H; Kang H
World J Gastroenterol; 2021 May; 27(17):1973-1992. PubMed ID: 34007134
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of muscarinic acetylcholine receptor type 3 gene polymorphisms in patients with primary biliary cholangitis and primary sclerosing cholangitis.
Greverath LM; Leicht E; Wald de Chamorro N; Wilde AB; Steinhagen LM; Lieb C; Schmelzle M; Chopra S; Shibolet O; Fischer J; Berg T; Tacke F; Müller T
Hepatol Res; 2020 Mar; 50(3):321-329. PubMed ID: 31747477
[TBL] [Abstract][Full Text] [Related]
39. Emerging drugs for the treatment of Primary Biliary Cholangitis.
Ali AH; Tabibian JH; Carey EJ; Lindor KD
Expert Opin Emerg Drugs; 2016; 21(1):39-56. PubMed ID: 26901615
[TBL] [Abstract][Full Text] [Related]
40. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis.
Qiu F; Tang R; Zuo X; Shi X; Wei Y; Zheng X; Dai Y; Gong Y; Wang L; Xu P; Zhu X; Wu J; Han C; Gao Y; Zhang K; Jiang Y; Zhou J; Shao Y; Hu Z; Tian Y; Zhang H; Dai N; Liu L; Wu X; Zhao W; Zhang X; Zang Z; Nie J; Sun W; Zhao Y; Mao Y; Jiang P; Ji H; Dong Q; Li J; Li Z; Bai X; Li L; Lin M; Dong M; Li J; Zhu P; Wang C; Zhang Y; Jiang P; Wang Y; Jawed R; Xu J; Zhang Y; Wang Q; Yang Y; Yang F; Lian M; Jiang X; Xiao X; Li Y; Fang J; Qiu D; Zhu Z; Qiu H; Zhang J; Tian W; Chen S; Jiang L; Ji B; Li P; Chen G; Wu T; Sun Y; Yu J; Tang H; He M; Xia M; Pei H; Huang L; Qing Z; Wu J; Huang Q; Han J; Xie W; Sun Z; Guo J; He G; Eric Gershwin M; Lian Z; Liu X; Seldin MF; Liu X; Chen W; Ma X
Nat Commun; 2017 Apr; 8():14828. PubMed ID: 28425483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
